Skip to main content
SpringerLink
Log in
Book cover

Encyclopedia of Clinical Neuropsychology pp 348–350Cite as

Asenapine

  • Reference work entry
  • First Online:

  • 6 Accesses

Generic Name

Asenapine

Brand Name

Saphris

Class

Antipsychotics, second generation, and mood stabilizer

Proposed Mechanism(s) of Action

Combination of central dopamine D2 and serotonin 5-HT2A receptor antagonism (sublingual)

Indication

For the treatment of schizophrenia and manic or mixed bipolar 1 episodes.

Off-Label Use

Agitation associated with a myriad of psychiatric conditions and dementia. Borderline personality disorder. Disruptive behavioral disorders associated with childhood.

Side Effects

Serious

Increased risk of mortality in elderly patients with dementia-related psychosis, mania. Extrapyramidal symptoms, prolongation of QT interval, and agranulocytosis.

Common

  • Headache, dizziness, somnolence, dry mouth, nausea, tachycardia, diarrhea, orthostatic hypotension, and weight gain

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   899.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD   1,099.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References and Readings

  • Cutler, A. J., Kalali, A. H., Weiden, P. J., Hamilton, J., & Wolfgang, C. D. (2008). Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. Journal of Clinical Psychopharmacology, 28(2 Suppl 1), S20–S28.

    Article  PubMed  Google Scholar 

  • Kane, J. M., Lauriello, J., Laska, E., Di Marino, M., & Wolfgang, C. D. (2008). Long-term efficacy and safety of iloperidone: Results from 3 clinical trials for the treatment of schizophrenia. Journal of Clinical Psychopharmacology, 28(2 Suppl 1), S29–S35.

    Article  PubMed  Google Scholar 

  • Kongsamut, S., Roehr, J. E., Cai, J., Hartman, H. B., Weissensee, P., Kerman, L. L., Tang, L., & Sandrasagra, A. (1996). Iloperidone binding to human and rat dopamine and 5-HT receptors. European Journal of Pharmacology, 317(2–3), 417–423.

    Article  PubMed  Google Scholar 

  • Physicians’ desk reference (71st ed.) (2017). Montvale: Thomson PDR.

    Google Scholar 

  • Potkin, S. G., Litman, R. E., Torres, R., & Wolfgang, C. D. (2008). Efficacy of iloperidone in the treatment of schizophrenia: Initial phase 3 studies. Journal of Clinical Psycopharmacology, 28(2 Suppl 1), S4–11.

    Article  Google Scholar 

  • Sainati, S. M., Hubbard, J. W., Chi, E., Grasing, K., & Brecher, M. B. (1995). Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. Journal of Clinical Pharmacology, 35(7), 713–720.

    Article  PubMed  Google Scholar 

  • Stahl, S. M. (2007). Essential psychopharmacology: The prescriber’s guide (2nd ed.). New York: Cambridge University Press.

    Google Scholar 

  • Szczepanik, A. M., Brougham, L. R., Roehr, J. E., Conway, P. G., Ellis, D. B., & Wilmot, C. A. (1996). Ex vivo studies with iloperidone (HP 873), a potential atypical antipsychotic with dopamine D2/5-hydroxytryptamine2 receptor antagonist activity. The Journal of Pharmacology and Experimental Therapeutics, 278(2), 913–920.

    PubMed  Google Scholar 

  • Weiden, P. J., Cutler, A. J., Polymeropoulos, M. H., & Wolfgang, C. D. (2008). Safety profile of iloperidone: A pooled analysis of 6-week acute-phase pivotal trials. Journal of Clinical Psychopharmacology, 28(2 Suppl 1), S12–S19.

    Article  PubMed  Google Scholar 

Additional Information

Download references

Author information

Authors and Affiliations

  1. College of Psychology, Nova Southeastern University, Fort Lauderdale, FL, USA

    Efrain Antonio Gonzalez

  2. Utah State University, Logan, UT, USA

    Efrain Antonio Gonzalez

Authors
  1. Efrain Antonio Gonzalez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Efrain Antonio Gonzalez .

Editor information

Editors and Affiliations

  1. Department of Physical Medicine and Rehabilitation, Virginia Commonwealth University, Richmond, VA, USA

    Jeffrey S. Kreutzer

  2. Kessler Foundation, Pleasant Valley Way, West Orange, NJ, USA

    John DeLuca

  3. Independent Practice, Wynnewood, PA, USA

    Bruce Caplan

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Gonzalez, E.A. (2018). Asenapine. In: Kreutzer, J.S., DeLuca, J., Caplan, B. (eds) Encyclopedia of Clinical Neuropsychology. Springer, Cham. https://doi.org/10.1007/978-3-319-57111-9_9261

Download citation

Publish with us

Policies and ethics

Search

Navigation